Intapp, Inc. (INTA)

Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	323.21	208.37	130.38	50.78	37.64	42.05
Cash & Short-Term Investments	323.21	208.37	130.38	50.78	37.64	42.05
Cash Growth	72.45%	59.82%	156.73%	34.93%	-10.50%	95.58%
Accounts Receivable	78.58	108.4	103.63	73.71	55.41	31.58
Other Receivables	5.42	2.74	0.88	3.2	0.86	1.14
Receivables	83.99	111.15	104.51	76.91	56.27	32.73
Prepaid Expenses	11.43	9.03	7.34	5.98	9.59	3.68
Restricted Cash	0.2	0.2	0.81	3.53	3.83	1.11
Other Current Assets	14.16	13.91	11.81	10.19	6.55	4.84
Total Current Assets	432.98	342.65	254.84	147.39	113.88	84.4
Property, Plant & Equipment	22.06	26.83	23.25	4.98	5.67	4.57
Goodwill	286.16	285.97	278.89	269.1	262.27	227.99
Other Intangible Assets	53.12	53.79	53.56	55.73	57.35	50.41
Long-Term Accounts Receivable	0.07	0.06	0.1	0.16	0.09	0.51
Long-Term Deferred Charges	17.55	18.5	16.53	14.76	10.41	8.24
Other Long-Term Assets	1.58	5.2	1.74	2.29	10.16	0.89
Total Assets	813.51	733	628.91	494.41	459.83	377.01
Accounts Payable	14.75	13.35	6.02	4.22	2.2	4.13
Accrued Expenses	50.81	54.11	51.39	48.78	41.37	21.69
Current Portion of Leases	4.9	6	4.7	-	-	-
Current Unearned Revenue	220.42	218.92	191.04	142.77	107.89	79.72
Other Current Liabilities	6.45	8.27	6.2	27.75	20.42	11.27
Total Current Liabilities	297.32	300.65	259.35	223.52	171.88	116.81
Long-Term Debt	-	-	-	-	275.59	279.46
Long-Term Leases	16.62	19.61	16.2	-	-	-
Long-Term Unearned Revenue	2.06	3.56	1.36	2.71	1.91	0.84
Long-Term Deferred Tax Liabilities	0.95	1.34	1.42	2.1	5.71	2.62
Other Long-Term Liabilities	4.25	4.61	9.38	10.2	18.17	3.81
Total Liabilities	321.21	329.76	287.7	238.53	473.26	403.53
Common Stock	0.08	0.08	0.07	0.06	0.03	0.02
Additional Paid-In Capital	998.24	891.68	797.64	643.23	128.94	69.18
Retained Earnings	-504.87	-487.18	-455.16	-385.74	-286.06	-238.2
Comprehensive Income & Other	-1.15	-1.34	-1.34	-1.67	-0.49	-1.67
Total Common Equity	492.3	403.24	341.21	255.88	-157.58	-170.66
Shareholders' Equity	492.3	403.24	341.21	255.88	-13.43	-26.52
Total Liabilities & Equity	813.51	733	628.91	494.41	459.83	377.01
Total Debt	21.52	25.61	20.9	-	275.59	279.46
Net Cash (Debt)	301.68	182.76	109.48	50.78	-237.96	-237.41
Net Cash Growth	86.84%	66.93%	115.59%	-	-	-
Net Cash Per Share	3.92	2.56	1.70	0.83	-8.51	-9.85
Filing Date Shares Outstanding	80.96	74.7	69.24	62.96	60.68	24.33
Total Common Shares Outstanding	80.58	74.62	68.57	62.74	29.44	24.33
Working Capital	135.66	42.01	-4.51	-76.13	-58.01	-32.41
Book Value Per Share	6.11	5.40	4.98	4.08	-5.35	-7.01
Tangible Book Value	153.03	63.48	8.76	-68.95	-477.2	-449.06
Tangible Book Value Per Share	1.90	0.85	0.13	-1.10	-16.21	-18.46
Machinery	-	6.09	4.72	3.16	3.94	2.45
Construction In Progress	-	0.16	0.39	0.28	-	1.73
Leasehold Improvements	-	5.6	5.9	5.28	5.42	2.4

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q